Two linear epitopes on the SARS-CoV-2 spike protein that elicit neutralising antibodies in COVID-19 patients

By C. Poh, G. Carissimo, Bei Wang, S. N. Amrun, C. Lee, R. Chee, Siew‐Wai Fong, N. Yeo, W. Lee, Anthony Torres‐Ruesta and 13 more. 2020

375 citations recorded by the source corpus.

Given the ongoing SARS-CoV-2 pandemic, identification of immunogenic targets against the coronavirus spike glycoprotein will provide crucial advances towards the development of sensitive diagnostic tools and potential vaccine candidate targets. In this study, using pools of overlapping linear B-cell peptides, we report two IgG immunodominant regions on SARS-CoV-2 spike glycoprotein that are recognised by sera from COVID-19 convalescent patients. Notably, one is specific to SARS-CoV-2, which is located in close proximity to the receptor binding domain. The other region, which is localised at the fusion peptide, could potentially function as a pan-SARS target. Functionally, antibody depletion assays demonstrate that antibodies targeting these immunodominant regions significantly alter virus neutralisation capacities. Taken together, identification and validation of these neutralising B-cell epitopes will provide insights towards the design of diagnostics and vaccine candidates against this high priority coronavirus. Characterisation of the human antibody response to SARS-CoV-2 can help the design of serological tests and vaccines. Here, the authors identify two linear epitopes in SARS-CoV-2 spike protein that elicit neutralising antibodies in several patients and could thus be useful for serology and vaccine development.

Subfields: Infectious Diseases, Molecular Biology

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Infectious Diseases

In Molecular Biology

Citations in the corpus

Elicitation of Potent Neutralizing Antibody Responses by Designed Protein Nanoparticle Vaccines for SARS-CoV-2 (2020, positive): “, 2016a; 2020) and the fact that it contains conserved epitopes that are targeted by neutralizing Abs such as the fusion peptide (Poh et al., 2020).”
Viral epitope profiling of COVID-19 patients reveals cross-reactivity and correlates of severity (2020, background): “A recent study showed that adding an excess of the fusion peptide reduced neutralization, implying that an antibody that binds the fusion peptide might contribute to neutralization by interfering with membrane fusion (21, 22).”